{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T16:38:56Z","timestamp":1790872736400,"version":"4.1.0"},"reference-count":36,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2007,1,20]]},"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p> To determine the risk factors for acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) after breast cancer. <\/jats:p><\/jats:sec><jats:sec><jats:title>Patients and Methods<\/jats:title><jats:p> We conducted a case-control study among women treated for breast cancer between 1985 and 2001 in French general hospitals, cancer centers, or clinics. We included 182 AML and MDS patients and 534 matched controls. Breast cancer characteristics, type of treatment, and family history of cancer were compared in both groups. <\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p> The risk of AML\/MDS was increased after topoisomerase-II inhibitor\u2013based chemotherapy (P &lt; 10<jats:sup>\u221216<\/jats:sup>) and was higher for mitoxantrone-based chemotherapy than for anthracycline-based chemotherapy (relative risk [RR] = 15.6; 95% CI, 7.1 to 34.2; and RR = 2.7; 95% CI, 1.7 to 4.5, respectively). After adjustment for other treatment components, the risk of AML\/MDS in patients who received radiotherapy was multiplied by 3.9 (95% CI, 1.4 to 10.8) but was not increased by alkylating agents. Patients receiving granulocyte colony-stimulating factor (G-CSF) support had an increased risk of AML\/MDS (RR = 6.3; 95% CI, 1.9 to 21), even when controlling for chemotherapy doses. Similar results were obtained when AML and MDS were considered separately. <\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p> This large case-control study demonstrates that the risk of AML\/MDS is much higher with mitoxantrone-based chemotherapy than with anthracyclines-based chemotherapy in a population of women recently treated for breast cancer. The risk of AML\/MDS associated with mitoxantrone must be kept in mind when using this drug to treat diseases other than breast cancer (eg, prostate cancer or multiple sclerosis). In addition, our study suggests the need to monitor the long-term effects of G-CSF therapy. <\/jats:p><\/jats:sec>","DOI":"10.1200\/jco.2006.05.9048","type":"journal-article","created":{"date-parts":[[2006,12,12]],"date-time":"2006-12-12T10:42:38Z","timestamp":1165920158000},"page":"292-300","source":"Crossref","is-referenced-by-count":128,"title":["Anthracyclines, Mitoxantrone, Radiotherapy, and Granulocyte Colony-Stimulating Factor: Risk Factors for Leukemia and Myelodysplastic Syndrome After Breast Cancer"],"prefix":"10.1200","volume":"25","author":[{"given":"Marie-C\u00e9cile","family":"Le Deley","sequence":"first","affiliation":[{"name":"From the Biostatistics and Epidemiology Unit, Department of Medicine, Radiophysics Unit, Hematology Unit, and Cytogenetics Laboratory, Institut Gustave-Roussy; L'Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale Unit 605, Villejuif; Clinique de Courlancy, Reims; H\u00f4pital Bretonneau, Tours; and the Hematology Department, H\u00f4pital Avicenne, Paris XIII University, Bobigny, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Suzan","sequence":"additional","affiliation":[{"name":"From the Biostatistics and Epidemiology Unit, Department of Medicine, Radiophysics Unit, Hematology Unit, and Cytogenetics Laboratory, Institut Gustave-Roussy; L'Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale Unit 605, Villejuif; Clinique de Courlancy, Reims; H\u00f4pital Bretonneau, Tours; and the Hematology Department, H\u00f4pital Avicenne, Paris XIII University, Bobigny, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Cutuli","sequence":"additional","affiliation":[{"name":"From the Biostatistics and Epidemiology Unit, Department of Medicine, Radiophysics Unit, Hematology Unit, and Cytogenetics Laboratory, Institut Gustave-Roussy; L'Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale Unit 605, Villejuif; Clinique de Courlancy, Reims; H\u00f4pital Bretonneau, Tours; and the Hematology Department, H\u00f4pital Avicenne, Paris XIII University, Bobigny, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzette","family":"Delaloge","sequence":"additional","affiliation":[{"name":"From the Biostatistics and Epidemiology Unit, Department of Medicine, Radiophysics Unit, Hematology Unit, and Cytogenetics Laboratory, Institut Gustave-Roussy; L'Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale Unit 605, Villejuif; Clinique de Courlancy, Reims; H\u00f4pital Bretonneau, Tours; and the Hematology Department, H\u00f4pital Avicenne, Paris XIII University, Bobigny, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akthar","family":"Shamsaldin","sequence":"additional","affiliation":[{"name":"From the Biostatistics and Epidemiology Unit, Department of Medicine, Radiophysics Unit, Hematology Unit, and Cytogenetics Laboratory, Institut Gustave-Roussy; L'Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale Unit 605, Villejuif; Clinique de Courlancy, Reims; H\u00f4pital Bretonneau, Tours; and the Hematology Department, H\u00f4pital Avicenne, Paris XIII University, Bobigny, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claude","family":"Linassier","sequence":"additional","affiliation":[{"name":"From the Biostatistics and Epidemiology Unit, Department of Medicine, Radiophysics Unit, Hematology Unit, and Cytogenetics Laboratory, Institut Gustave-Roussy; L'Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale Unit 605, Villejuif; Clinique de Courlancy, Reims; H\u00f4pital Bretonneau, Tours; and the Hematology Department, H\u00f4pital Avicenne, Paris XIII University, Bobigny, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phanie","family":"Clisant","sequence":"additional","affiliation":[{"name":"From the Biostatistics and Epidemiology Unit, Department of Medicine, Radiophysics Unit, Hematology Unit, and Cytogenetics Laboratory, Institut Gustave-Roussy; L'Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale Unit 605, Villejuif; Clinique de Courlancy, Reims; H\u00f4pital Bretonneau, Tours; and the Hematology Department, H\u00f4pital Avicenne, Paris XIII University, Bobigny, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florent","family":"de Vathaire","sequence":"additional","affiliation":[{"name":"From the Biostatistics and Epidemiology Unit, Department of Medicine, Radiophysics Unit, Hematology Unit, and Cytogenetics Laboratory, Institut Gustave-Roussy; L'Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale Unit 605, Villejuif; Clinique de Courlancy, Reims; H\u00f4pital Bretonneau, Tours; and the Hematology Department, H\u00f4pital Avicenne, Paris XIII University, Bobigny, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Fenaux","sequence":"additional","affiliation":[{"name":"From the Biostatistics and Epidemiology Unit, Department of Medicine, Radiophysics Unit, Hematology Unit, and Cytogenetics Laboratory, Institut Gustave-Roussy; L'Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale Unit 605, Villejuif; Clinique de Courlancy, Reims; H\u00f4pital Bretonneau, Tours; and the Hematology Department, H\u00f4pital Avicenne, Paris XIII University, Bobigny, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Hill","sequence":"additional","affiliation":[{"name":"From the Biostatistics and Epidemiology Unit, Department of Medicine, Radiophysics Unit, Hematology Unit, and Cytogenetics Laboratory, Institut Gustave-Roussy; L'Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale Unit 605, Villejuif; Clinique de Courlancy, Reims; H\u00f4pital Bretonneau, Tours; and the Hematology Department, H\u00f4pital Avicenne, Paris XIII University, Bobigny, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"R1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.1440"},{"key":"R2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/90.21.1601"},{"key":"R3","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/90.21.1587"},{"key":"R4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)03301-7"},{"key":"R5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.05.029"},{"key":"R6","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdg204"},{"key":"R7","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2401787"},{"key":"R8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.15.2836"},{"key":"R9","unstructured":"Cutuli B, Janvier M, de la Rochefordiere A, et al: Leukemia and pre-leukemic conditions occurring after treatment of breast cancer. Presse Med 29:135,2000-138,"},{"key":"R10","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008375016038"},{"key":"R11","doi-asserted-by":"publisher","DOI":"10.1054\/bjoc.2000.1196"},{"key":"R12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.03.114"},{"key":"R13","unstructured":"Breslow NE, Day NE: Statistical methods in cancer research. Volume I: The analysis of case-control studies. IARC Sci Publ 32:5,1980-338,"},{"key":"R14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.04.100"},{"key":"R16","doi-asserted-by":"publisher","DOI":"10.3109\/02841869209088912"},{"key":"R17","doi-asserted-by":"crossref","unstructured":"Philpott NJ, Bevan DH, Gordon-Smith EC: Secondary leukaemia after MMM combined modality therapy for breast carcinoma. Lancet 341:1289,1993,","DOI":"10.1016\/0140-6736(93)91199-V"},{"key":"R18","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.annonc.a010725"},{"key":"R19","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2400876"},{"key":"R20","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1704291"},{"key":"R21","unstructured":"Arkad'eva MA, Zaridze DG: The risk of the occurrence of acute nonlymphoblastic leukemia in patients with malignant neoplasms undergoing radio- and chemotherapy. Vopr Onkol 37:1086,1991-1090,"},{"key":"R22","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/87.10.732"},{"key":"R23","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/78.3.459"},{"key":"R24","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.08.137"},{"key":"R25","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.04.148"},{"key":"R26","unstructured":"Fumoleau P, Roche H, Kerbrat P, et al: Long-term benefit\/risk ratio of epirubicin-based adjuvant chemotherapy in operable breast cancer patients: 7-year analysis in 3577 pts of French Adjuvant Study Group (FASG) trials. Proc Am Soc Clin Oncol 23:23,2003,  (abstr 91)"},{"key":"R27","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199206253262605"},{"key":"R28","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.7.1557"},{"key":"R29","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.annonc.a059008"},{"key":"R30","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.09.006"},{"key":"R31","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-08-2405"},{"key":"R32","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/83.14.1013"},{"key":"R33","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1987.40"},{"key":"R34","doi-asserted-by":"publisher","DOI":"10.1007\/BF02990948"},{"key":"R35","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198210143071601"},{"key":"R36","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V58.4.759.bloodjournal584759"},{"key":"R37","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402764"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2006.05.9048","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T20:12:15Z","timestamp":1653509535000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2006.05.9048"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,1,20]]},"references-count":36,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2007,1,20]]}},"alternative-id":["10.1200\/JCO.2006.05.9048"],"URL":"https:\/\/doi.org\/10.1200\/jco.2006.05.9048","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,1,20]]}}}